Survival and imaging of patients with R/R PCNSL treated with commercial anti-CD19 CAR T-cells. (A) OS and PFS. Median OS was not reached. Median PFS was 122 days for the whole cohort, increasing to 210 days for responders, vs 29 days for non-responders. (B) Patient 3: right frontal lesion at baseline and CR 2 months after CAR T-cell infusion. (C) Illustration of the flare effect suspected in patient 6: appearance of a left periventricular lesion 1 month after CAR T-cell infusion that dramatically decreased 2 and 5 months later. Despite high suspicion of a flare effect, response was reported as progressive disease according to the IPCG criteria, thus potentially underestimating PFS.